Tuberculosis
Researchers at the University of Liverpool School Tropical Medicine have presented data on a new treatment regimen for drug-resistant tuberculosis (TB). The study, which took place from January 2020 to December 2023, compared a standard injectable-containing regimen to an all-oral regimen for multidrug- and rifampicin-resistant TB (MDR/RR-TB). The results
Tuberculosis
Research at the Swiss Tropical and Public Health Institute has shed light on the significant contribution of Mycobacterium tuberculosis complex (MTBC) lineage 1 (L1) to human tuberculosis (TB) cases, particularly in low- to middle-income countries in South and Southeast Asia, and East Africa. Despite its restricted geographical range, L1 is
AIDS treatment
In a landmark study conducted at the Mildmay-Uganda Hospital from 2018 to 2023, researchers analyzed data from 235 people living with HIV (PLHIV) and found that early drug resistance mutations testing and individualized antiretroviral therapy (ART) can significantly improve HIV treatment outcomes. The study, led by Collins Ankunda and colleagues,
HIV
Research conducted across 31 provincial-level administrative divisions in China between April and June 2023 has found that transmitted drug resistance (TDR) among individuals newly diagnosed with HIV-1 in China exceeds 10%. The study analyzed demographic information and blood samples from 6,654 participants and found that TDR prevalence was 11.
HIV
Researchers at the University of Campania 'Luigi Vanvitelli' in Naples, Italy, have made a significant breakthrough in HIV/AIDS treatment by exploring new combination therapies. Despite the progress of antiretroviral therapy, some patients with multidrug-resistant (MDR) HIV infection continue to struggle with the disease. The study investigated the
HIV
Research conducted in Guangxi, China, from 2019 to 2022 has revealed a significant problem with pretreatment drug resistance (PDR) in HIV/AIDS therapy. The study, led by researchers from Guangxi Medical University, found that the overall prevalence of PDR was 8.4% among newly diagnosed, antiretroviral therapy (ART)-naive individuals.
HIV
Researchers at the University of Douala in Cameroon have identified a high level of HIV-1 drug resistance mutations among adolescents with detectable viremia. The study, published in the Journal of Antimicrobial Chemotherapy, analyzed 127 plasma and paired buffy-coat samples collected from 90 adolescents between February and September 2021. The findings
HIV
In a landmark study conducted at the Mildmay-Uganda Hospital from 2018 to 2023, researchers analyzed data from 235 people living with HIV (PLHIV) and found that early drug resistance mutations testing and individualized antiretroviral therapy (ART) can significantly improve HIV treatment outcomes. The study, led by Collins Ankunda and colleagues,
Drug resistance
Researchers at the University of Campania 'Luigi Vanvitelli' in Naples, Italy, have made a significant breakthrough in HIV/AIDS treatment by exploring new combination therapies. Despite the progress of antiretroviral therapy, some patients with multidrug-resistant (MDR) HIV infection continue to struggle with the disease. The study investigated the
Cancer treatment
Researchers at China Medical University have published a comprehensive review on innovative strategies for targeted therapy in ovarian cancer, emphasizing the importance of multimodal integrative approaches that combine pH-sensitive nanocarriers, epigenetic regulators, and immune modulation systems. This study highlights the potential of these approaches in reversing therapeutic resistance and enhancing
AIDS (Disease)
Research conducted across 31 provincial-level administrative divisions in China between April and June 2023 has found that transmitted drug resistance (TDR) among individuals newly diagnosed with HIV-1 in China exceeds 10%. The study analyzed demographic information and blood samples from 6,654 participants and found that TDR prevalence was 11.
Drug resistance
Recent research highlights the significance of monitoring transmitted drug resistance to guide first-line antiretroviral therapy and control the rising HIV epidemic in Turkey. A study conducted at Hacettepe University Hospital analyzed 104 consecutive ART-naïve individuals living with HIV, identifying 97 from 25 different cities in Turkey and 7 from 5
